Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938963 | 0.75 | NPC1 (0.42) | — | |
| SCHEMBL11784689 | 0.70 | RAB9A (0.42) | — | |
| SCHEMBL9115600 | 0.68 | DYRK1A (0.45) | FGFR1ABCG2GSK3B | |
| SCHEMBL18193678 | 0.67 | L3MBTL1 (0.53) | FGFR1 | |
| SCHEMBL533008 | 0.65 | AKR1C3 (0.32) | MCL1 | |
| SCHEMBL5708068 | 0.65 | NPC1 (0.35) | — | |
| SCHEMBL19413409 | 0.64 | ENPP2 (0.48) | FGFR1MCL1 | |
| SCHEMBL5345055 | 0.63 | FGFR1 (0.37) | FGFR1MCL1 | |
| SCHEMBL8081183 | 0.63 | KDM4E (0.38) | FGFR1MCL1 | |
| SCHEMBL23638490 | 0.62 | TRPM5 (0.38) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | UBE INDUSTRIES, LTD. (JP) | 2003-11-20 | — | — | US | claimed |
| EP-1254897-A1 | TRICYCLIC COMPOUNDS | Ube Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | claimed |
| US-7309718-B2 | Dibenzocycloheptene compound | UBE INDUSTRIES, LTD. (JP) | 2007-12-18 | — | — | US | disclosed |
| US-20040180884-A1 | Dibenzocycloheptene compound | UBE INDUSTRIES, LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1408033-A1 | DIBENZOCYCLOHEPTENE COMPOUND | Ube Industries, Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | UBE INDUSTRIES, LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1254897-A1 | TRICYCLIC COMPOUNDS | Ube Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180884-A1 | Dibenzocycloheptene compound | LTB4R2, LTA4H, LTC4S | FGFR1 2445/4885ABCG2 1289/4885GSK3B 3318/4885 |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | CYSLTR2, CYSLTR1, LTC4S | FGFR1 3784/4885ABCG2 1075/4885GSK3B 3831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.